AAAAAA

   
Results: 1-25 | 26-29
Results: 1-25/29
The CDC Guidelines for Prevention of Infections: rule with reason
Authors: Przepiorka, D
Citation: D. Przepiorka, The CDC Guidelines for Prevention of Infections: rule with reason, CYTOTHERAPY, 3(1), 2001, pp. 37-39
Characteristics of human dendritic cells generated in a microgravity analog culture system
Authors: Savary, CA Grazziutti, ML Przepiorka, D Tomasovic, SP McIntyre, BV Woodside, DG Pellis, NR Pierson, DL Rex, JH
Citation: Ca. Savary et al., Characteristics of human dendritic cells generated in a microgravity analog culture system, IN VITRO-AN, 37(4), 2001, pp. 216-222
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia
Authors: Bibawi, S Abi-Said, D Fayad, L Anderlini, P Ueno, NT Mehra, R Khouri, I Giralt, S Gajewski, J Donato, M Claxton, D Braunschweig, I van Besien, K Andreeff, M Andersson, BS Estey, EH Champlin, R Przepiorka, D
Citation: S. Bibawi et al., Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia, AM J HEMAT, 67(4), 2001, pp. 227-233
Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey
Authors: Hsu, B May, R Carrum, G Krance, R Przepiorka, D
Citation: B. Hsu et al., Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey, BONE MAR TR, 28(10), 2001, pp. 945-950
Dendritic cell-mediated stimulation of the in vitro lymphocyte response toAspergillus
Authors: Grazziutti, M Przepiorka, D Rex, JH Braunschweig, I Vadhan-Raj, S Savary, CA
Citation: M. Grazziutti et al., Dendritic cell-mediated stimulation of the in vitro lymphocyte response toAspergillus, BONE MAR TR, 27(6), 2001, pp. 647-652
Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes
Authors: Kornblau, SM Stiouf, I Snell, V Przepiorka, D Stephens, LC Champlin, R Marini, FC
Citation: Sm. Kornblau et al., Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes, CANCER RES, 61(8), 2001, pp. 3355-3360
Chronic graft-versus-host disease after allogeneic blood stem cell transplantation
Authors: Przepiorka, D Anderlini, P Saliba, R Cleary, K Mehra, R Khouri, I Huh, YO Giralt, S Braunschweig, I van Besien, K Champlin, R
Citation: D. Przepiorka et al., Chronic graft-versus-host disease after allogeneic blood stem cell transplantation, BLOOD, 98(6), 2001, pp. 1695-1700
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Authors: Giralt, S Thall, PF Khouri, I Wang, XM Braunschweig, I Ippolitti, C Claxton, D Donato, M Bruton, J Cohen, A Davis, M Andersson, BS Anderlini, P Gajewski, J Kornblau, S Andreeff, M Przepiorka, D Ueno, NT Molldrem, J Champlin, R
Citation: S. Giralt et al., Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation, BLOOD, 97(3), 2001, pp. 631-637
Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors
Authors: Przepiorka, D Smith, TL Folloder, J Anderlini, P Chan, KW Korbling, M Lichtiger, B Norfleet, F Champlin, R
Citation: D. Przepiorka et al., Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors, BLOOD, 97(11), 2001, pp. 3405-3410
High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer
Authors: Braunschweig, I Mirza, NQ Rondon, G Lauppe, J Mehra, R Gajewski, J Korbling, M Huh, YO Geisler, D Gee, AP Champlin, R Przepiorka, D
Citation: I. Braunschweig et al., High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer, CYTOTHERAPY, 2(2), 2000, pp. 105-110
Tacrolimus does not abrogate the increased risk of acute graft-versus-hostdisease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB I and HLA-DQB I
Authors: Przepiorka, D Saliba, R Cleary, K Fischer, H Tonai, R Fritsche, H Khouri, IF Folloder, J Ueno, NT Mehra, R Ippoliti, C Giralt, S Gajewski, J Donato, M Claxton, D Braunschweig, I van Besien, K Anderlini, P Andersson, BS Champlin, R
Citation: D. Przepiorka et al., Tacrolimus does not abrogate the increased risk of acute graft-versus-hostdisease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB I and HLA-DQB I, BIOL BLOOD, 6(2A), 2000, pp. 190-197
Clinical protocol - Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease
Authors: Heslop, H Rooney, C Brenner, M Krance, R Carrum, G Gahn, B Bollard, C Khan, S Gee, A Popat, U Gresik, M Przepiorka, D Kuehnle, I Grilley, B
Citation: H. Heslop et al., Clinical protocol - Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease, HUM GENE TH, 11(10), 2000, pp. 1465-1475
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies
Authors: Tran, HT Madden, T Petropoulos, D Worth, LL Felix, EA Sprigg-Saenz, HA Choroszy, M Danielson, M Przepiorka, D Chan, KW
Citation: Ht. Tran et al., Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies, BONE MAR TR, 26(5), 2000, pp. 463-470
Clinical trials of HER-2/neu-specific vaccines
Authors: Murray, JL Przepiorka, D Ioannides, CG
Citation: Jl. Murray et al., Clinical trials of HER-2/neu-specific vaccines, SEMIN ONCOL, 27(6), 2000, pp. 71-75
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
Authors: Nash, RA Antin, JH Karanes, C Fay, JW Avalos, BR Yeager, AM Przepiorka, D Davies, S Petersen, FB Bartels, P Buell, D Fitzsimmons, W Anasetti, C Storb, R Ratanatharathorn, V
Citation: Ra. Nash et al., Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors, BLOOD, 96(6), 2000, pp. 2062-2068
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
Authors: Przepiorka, D Kernan, NA Ippoliti, C Papadopoulos, EB Giralt, S Khouri, I Lu, JG Gajewski, J Durett, A Cleary, K Champlin, R Andersson, BS Light, S
Citation: D. Przepiorka et al., Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease, BLOOD, 95(1), 2000, pp. 83-89
Long-term outcome of a Phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients
Authors: Gajewski, JL Nimer, S Saliba, RM Thomas, M Przepiorka, D Giralt, S von Besien, K Mehra, R Andersson, B Chan, KW Ippoliti, C Warkinten, D Feig, S Territo, M Schiller, G Lebkowski, J Moseley, AM Lloyd, K von Hoeff, M Okarma, T Champlin, R
Citation: Jl. Gajewski et al., Long-term outcome of a Phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients, CYTOTHERAPY, 1(5), 1999, pp. 401-407
Debulking blood stem cell collections by density gradient centrifugation in a closed-vessel system
Authors: Przepiorka, D Lu, JG Anderlini, P Korbling, M Donato, M Champlin, R Gee, AP van Vlasselaer, P
Citation: D. Przepiorka et al., Debulking blood stem cell collections by density gradient centrifugation in a closed-vessel system, CYTOTHERAPY, 1(2), 1999, pp. 111-117
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
Authors: Przepiorka, D van Besien, K Khouri, I Hagemeister, F Samuels, B Folloder, J Ueno, NT Molldrem, J Mehra, R Korbling, M Giralt, S Gajewski, J Donato, M Cleary, K Claxton, D Braunschweig, I Andersson, B Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma, ANN ONCOL, 10(5), 1999, pp. 527-532
Hematopoietic stem cell transplantation for childhood myeloid malignanciesafter high-dose thiotepa, busulfan and cyclophosphamide
Authors: Worth, LL Tran, H Petropoulos, D Culbert, SC Mullen, CA Roberts, WM Przepiorka, D Chan, KW
Citation: Ll. Worth et al., Hematopoietic stem cell transplantation for childhood myeloid malignanciesafter high-dose thiotepa, busulfan and cyclophosphamide, BONE MAR TR, 24(9), 1999, pp. 947-952
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation
Authors: Przepiorka, D Khouri, I Ippoliti, C Ueno, NT Mehra, R Korbling, M Giralt, S Gajewski, J Fischer, H Donato, M Cleary, K Claxton, D Chan, KW Braunschweig, I van Besien, K Andersson, BS Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation, BONE MAR TR, 24(7), 1999, pp. 763-768
Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study
Authors: Maltazou, H Whimbey, E Abi-Said, D Przepiorka, D Champlain, R Goodrich, JM
Citation: H. Maltazou et al., Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study, BONE MAR TR, 24(6), 1999, pp. 665-669
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation
Authors: Przepiorka, D Devine, SM Fay, JW Uberti, JP Wingard, JR
Citation: D. Przepiorka et al., Practical considerations in the use of tacrolimus for allogeneic marrow transplantation, BONE MAR TR, 24(10), 1999, pp. 1053-1056
Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation
Authors: Przepiorka, D Petropoulos, D Mullen, CA Danielson, M Mattewada, V Chan, KW
Citation: D. Przepiorka et al., Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation, BONE MAR TR, 23(12), 1999, pp. 1291-1295
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia
Authors: Przepiorka, D Khouri, I Thall, P Mehra, R Lee, MS Ippoliti, C Giralt, S Gajewski, J van Besien, K Andersson, B Korbling, M Deisseroth, AB Champlin, R
Citation: D. Przepiorka et al., Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia, BONE MAR TR, 23(10), 1999, pp. 977-981
Risultati: 1-25 | 26-29